

Anti-Drug Antibody (Immunogenicity) Assay Services



Large Molecule Drug Discovery & Development Services:

Immunogenicity is the ability of a substance, like an antigen, to trigger an immune response. In protein therapeutics, this can lead to anti-drug antibodies that neutralize the drug, alter pharmacokinetics, or attack essential proteins. Regulatory agencies mandate immunogenicity screening for all protein drugs to mitigate these risks.

What Prolytix Does for You?

- › Prolytix specializes in developing and validating custom anti-drug antibody assays to assess therapeutic protein immunogenicity. We create tailored controls, leveraging cutting-edge techniques and instrumentation. Our GLP FDA-audited facility ensures reliable testing for your samples, delivering precision and quality aligned with your product's needs

What Therapies can Prolytix Support?

- › Monoclonal Antibodies
- › Antibody Fragments
- › Antibody Drug Conjugates (ADCs)
- › Fusion Proteins
- › Gene Therapies
- › Oligonucleotides

What Makes Prolytix Immunogenicity Experts?

- › Experience supporting studies in rodents, humans, and non-human primates
- › Able to support samples globally, including Australia and Europe
- › FDA / MHRA Inspected Facility for GLP Compliance

What is Our Approach?

- › Multiple ADA screening assay formats with high reliability and sensitivity
- › Formats to detect antibodies with desired specificities (IgM, IgG subclasses etc.)
- › Acid Dissociation
- › Affinity Capture and Elution (ACE)
- › Solid Phase Extraction and Acid Dissociation (SPEAD)

Learn More: info@goprolytix.com

